Galecto

Galecto P/TBV

Delisted·Sep 22, 2026

The Price to Tangible Book Value (P/TBV) of Galecto (GLTO) as of Oct 27, 2026 is 7.03. In the previous year, Price to Tangible Book Value (P/TBV) was 106.80 — a change of -93.41% (lower).

P/TBV

7.03

YoY

-93.41%

Last updated:

Price to Tangible Book Value (P/TBV) of Galecto is 2025 7.03 . Price to Tangible Book Value (P/TBV) of Galecto was 2024 106.80 . It decreases by -93.41% lower compared to the previous year.

The Galecto P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
55.15 USD
Jan 1, 2019
34.88 USD
Jan 1, 2020
10.22 USD
Jan 1, 2021
14.42 USD
Jan 1, 2022
27.38 USD
Jan 1, 2023
52.30 USD
Jan 1, 2024
106.80 USD
Jan 1, 2025
7.03 USD
The Galecto P/TBV history
YEARP/TBVYoY
7.03-93.41%
106.80+104.23%
52.30+91.00%
27.38+89.83%
14.42+41.17%
10.22-70.71%
34.88-36.75%
55.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Galecto Stock analysis

What does Galecto do? Galecto, Inc. develops small molecule therapeutics targeting galectin-3 and LOXL2 for cancer and fibrotic diseases. The company focuses on GB0139 for Idiopathic Pulmonary Fibrosis (IPF), GB1211 for oncology and liver cirrhosis, and GB2064 for myelofibrosis. These products are designed to address biological processes central to these conditions. The firm targets medical professionals and healthcare institutions seeking novel treatments for fibrotic and oncological disorders. Galecto's revenue streams come from the development and potential future commercialization of its therapeutic candidates. The company is a clinical-stage biotechnology firm, meaning it is currently in the development phase and has not yet generated revenue from product sales. The primary buyers of Galecto's products will be healthcare providers and pharmaceutical distributors once the drugs are approved and marketed. The company's product pipeline includes GB0139 for IPF, GB1211 for oncology and liver cirrhosis, and GB2064 for myelofibrosis. These products are developed as small molecule inhibitors targeting specific biological processes. Galecto's focus on clinical-stage development indicates that it is still in the research and testing phase, with no current revenue from product sales. Galecto is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Galecto stock

Price to Tangible Book Value (P/TBV) of Galecto is 7.03 in 2025.

Price to Tangible Book Value (P/TBV) of Galecto changed from 106.80 to 7.03, representing a -93.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Galecto since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Galecto with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Galecto

All Key Metrics — Galecto